Yes, Hepatitis C Can Cause Peripheral Arthritis with Positive RF and Elevated ESR
Hepatitis C virus infection is a well-established cause of peripheral arthritis that frequently presents with positive rheumatoid factor (in >50% of cases) and elevated inflammatory markers including ESR, making it a critical differential diagnosis in your patient. 111
Understanding HCV-Related Arthritis
HCV-associated arthritis occurs in approximately 4-5% of infected patients, though arthralgia is much more common 1. The clinical presentation you describe—peripheral arthritis with positive RF and markedly elevated ESR (110 mm/h)—is entirely consistent with HCV-related arthropathy.
Two Distinct Patterns
Symmetrical Polyarthritis (Most Common):
- Mimics rheumatoid arthritis with symmetrical involvement of wrists and hands
- Positive RF in more than 50% of patients
- Elevated inflammatory markers (ESR, CRP) 12
- Critical distinction: Non-deforming, no bone erosions, no rheumatoid nodules 11
Intermittent Mono-oligoarthritis:
- Affects medium/large joints, especially ankles
- Often associated with cryoglobulinemic vasculitis
- Acute course with frequent relapses 1
Key Diagnostic Differentiators
To distinguish HCV arthritis from true rheumatoid arthritis:
- Anti-CCP antibodies are the critical test: Rarely positive in HCV arthritis but almost always positive in RA 113
- Check for cryoglobulins—positive in 15-23% of HCV arthritis cases 23
- Look for complement consumption (low C3/C4) suggesting cryoglobulinemia 2
- Plain radiographs should show absence of erosive changes 13
Common Pitfall
Do not assume RA simply because RF is positive and ESR is elevated. RF positivity occurs in 50-80% of HCV patients with arthritis 45, and your patient's ESR of 110 is consistent with HCV-related inflammatory disease 2.
Management Algorithm
Step 1: Confirm HCV-Associated Arthritis
- Verify HCV RNA positivity
- Order anti-CCP antibodies (should be negative)
- Check cryoglobulins and complement levels
- Obtain hand/wrist radiographs (should show no erosions)
Step 2: Etiologic Treatment (Primary Approach)
- Initiate interferon-free direct-acting antivirals (DAAs) as first-line therapy 11
- Viral eradication addresses the root cause and is highly effective 1
Step 3: Symptomatic Management
- Low-dose glucocorticoids (safe and effective) 11
- Hydroxychloroquine (well-tolerated option) 115
- Avoid or use cautiously: Methotrexate and leflunomide due to hepatotoxicity concerns 11
- Rituximab: First-choice for aggressive disease or cryoglobulinemic vasculitis 11
Important Caveats
Medication Safety Concerns:
- Traditional DMARDs (methotrexate, leflunomide) carry hepatotoxicity risks and are often contraindicated 11
- Anti-TNF agents are safe in HCV patients but generally excessive for HCV arthritis 1
- NSAIDs can be used but monitor liver function
Prognosis: HCV arthritis typically runs a less aggressive, non-deforming course compared to RA 145, which is reassuring for long-term joint outcomes but doesn't diminish the need for viral eradication to prevent systemic complications.
Clinical Bottom Line
Your patient's presentation is classic for HCV-related arthritis. The positive RF and ESR of 110 do not indicate RA—they reflect HCV-driven immune dysregulation 26. Order anti-CCP antibodies immediately; if negative, prioritize DAA therapy for viral eradication while managing symptoms with low-dose steroids and/or hydroxychloroquine. This approach addresses both the underlying cause and improves quality of life while avoiding unnecessary immunosuppression.